Description
Anti-angiogenesis Strategies in Cancer Therapeutics provides a detailed look at the current status and future directions in the discovery and development of novel anti-angiogenesis strategies in oncology. This book highlights the different mechanisms involved in the modulation of angiogenesis, including inflammation, thrombosis, and microRNA, and shows how nanotechnology can further enhance the potential of existing and new anti-angiogenesis approaches.
Written for industry scientists, researchers, oncologists, hematologists, and professors and students in the field, this comprehensive book covers all aspects of anti-angiogenesis strategies and their differences.
- Covers important preclinical models and clinical trials in the discovery and development of novel anti-angiogenesis agents
- Reviews FDA-approved anti-angiogenesis agents
- Illustrates the value of nanotechnology in improving the utility of anti-angiogenesis agents
- Offers insight into the development of novel anti-angiogenesis agents and future direction in this area
Chapter
Chapter 1 - Angiogenesis and Anti-Angiogenesis Strategies in Cancer
Current Examples of Cancer Treatment Agents that Block Angiogenesis
Side Effects of Angiogenesis Inhibitors
Angiogenesis and Angiogenesis Inhibitors: Potential Anti-cancer Therapeutic Efficacy
Additional Anti-angiogenesis Strategies in Cancers
Alpha 3 Chain of Type IV Collagen
Matrix Metalloproteinases
Small Molecule Integrin Antagonists
Nutraceutical-Derived Polyphenols
Anti-angiogenesis Therapy in Hematologic Cancer: Multiple Myeloma
Anti-coagulants and Angiogenesis
Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs
Standard Chemotherapy Versus Angiogenesis Inhibitors
Anti-angiogenesis Agents and Thrombosis
Diagnostic Imaging of Angiogenesis
microRNA and Angiogenesis Modulation
Chapter 2 - Models for Assessing Anti-Angiogenesis Agents: Appraisal of Current Techniques
Chick Chorioallantoic Membrane
Subcutaneous and Orthotopic Xenografts
Three-Dimensional Matrix Array Ultrasound Molecular Imaging
Coculture of Human Cancer Cells with Human Microvascular Endothelial Cells
Chapter 3 - Anti-Angiogenesis in Multiple Myeloma
Angiogenesis in Multiple Myeloma
Thalidomide and its Analogs
Tyrosine Kinase Inhibitors (TKIs)
Chapter 4 - Interface between Thrombosis, Inflammation, and Angiogenesis in Cancer Progression
Cancer-associated Thrombosis
TF-VIIa-PAR2 Signaling Regulates Angiogenesis
TF-VIIa-PAR2 Signaling Regulates Inflammation
Role of TF-VIIa in Cellular Signaling
Chapter 5 - microRNAs and Angiogenesis
Specific miRNAs and Angiogenesis
Endothelial Cells and miRNAs
miRNAs and Hormone-Stimulated Angiogenesis
Clinical Targeting of miRNAs
Chapter 6 - Naturally Occurring Angiogenesis Inhibitors
Nutraceutical-Derived Polyphenol Angiogenesis Inhibitors
Marine Nonglycosaminoglycan Sulfated Glycans
Chapter 7 - Integrin Antagonists and Angiogenesis
Cell Surface Membrane Integrins as Potential Drug Discovery Targets
Integrin αvβ3 Antagonists Promote Tumor Regression by Inducing Apoptosis of Angiogenic Blood Vessels
Exploitation of αvβ3 for Targeted Delivery of Viral or Pharmacologic Agents
Combination of αvβ3 Ligands and Tumor Imaging and Radiotherapy
Antagonists of Integrins αvβ3 and αvβ5 Inhibit Angiogenesis
Integrin αvβ3 Antagonists Versus Anti-αvβ3 and αvβ5
αvβ3 Ligands: Issues in the Development of αvβ3 Antagonists as Therapeutics
Integrin–hormone Crosstalk: Integrin Receptor-Mediated Actions of Thyroid Hormone
Chapter 8 - Tyrosine Kinase Inhibitors and Angiogenesis
Examples of Specific TKIs
Impact of Angiogenesis-Active TKIs on Clinical Outcomes
Chapter 9 - Tetraiodothyroacetic Acid at Integrin αvβ3: A Model of Pharmaceutical Anti-Angiogenesis
Thyroid Hormone is a Proangiogenic Agent and Tetrac is an Anti-angiogenic Agent
Tetrac, NDAT, and Angiogenesis-relevant Gene Expression and microRNA Expression
Tetrac, NDAT, and Actions of Vascular Growth Factors
Tetrac and NDAT Actions on Endothelial Cells
Anti-angiogenesis of NDAT in the Retina
Anti-angiogenesis of NDAT in Human Tumor Xenografts
Action of NDAT on Mechanisms of Vascular Sprouting
Side Effect Profile of NDAT
Chapter 10 - Anti-Angiogenesis Therapy and its Combination with Chemotherapy: Impact on Primary Tumor and its Metastasis
Biomarkers of Angiogenesis
Impact of Angiogenesis on Tumor Growth and Metastasis
Current Anti-angiogenic Therapies
Bevacizumab in Breast Cancer
Monoclonal Antibodies in Other Cancers
Tyrosine Kinase Inhibitors
Problems Encountered with Anti-angiogenic Therapy
Distinctive Features Of Tumor-Related Angiogenesis
Interstitial Pressure Increase
Angiogenesis and Thrombosis
Novel Anti-angiogenesis Strategies
Anti-angiogenesis and Nanotargeting
Chapter 11 - Application of Nanotechnology to Target Tumor Angiogenesis in Cancer Therapeutics
Integrin αvβ3 Targeting with Nanoparticles
Integrin αvβ3 Targeting with Tetrac Nanoformulation
Gene Therapy Delivery with Nanoparticles
Chapter 12 - New Directions in Anti-Angiogenesis Research
Integrin αvβ3 and Growth Factors
Transduction of Growth Factor Signals
Inflammation-Related Signaling
Anti-Angiogenesis Strategies in Cancer Therapies
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
